IF 2014

Welcome to the Annals of Transplantation

Annals of Transplantation is one of the fast-developing journals open to all scientists and fields of transplant medicine and related research. The journal is published quarterly and provides extensive coverage of the most important advances in transplantation.
Using an electronic on-line submission and peer review tracking system, Annals of Transplantation is committed to rapid review and publication. The average time... read more

Published: 2015-10-06

Predictors of Survival in Hepatocellular Carcinoma Patients

Hale Gokcan, Nurten Savaş, Derya Oztuna, Gokhan Moray, Fatih Boyvat, Mehmet Haberal

(Department of Gastroenterology, Ankara Yüksek Ihtisas Research and Training Hospital, Ankara, Turkey)

Ann Transplant 2015; 20:596-603

DOI: 10.12659/AOT.894878

BACKGROUND: Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide, with an incidence equal to the death rate.
MATERIAL AND METHODS: We aimed to detect the prognostic factors for HCC patients. We retrospectively analyzed 12 years data of 115 patients who have biopsy-proven HCC. Clinical and demographic characteristics of patients with treatment modalities, survival rates, and prognostic factors were analyzed.
RESULTS: There were 93 male patients, and the mean age was 63.5±11.8 years. Most patients had cirrhosis due to hepatitis virus infection. Median follow-up time was 17 months (1 month–9.5 years) after the diagnosis of HCC. The nodule was single in 43 (37.4%) patients, there were 2–3 nodules in 30 (26.1%), and >3 or diffuse nodules in 42 (36.5%) patients. Distribution of treatment modalities was as follows: 23 (20%) patients had liver transplantation, 15 (13%) had HCC resection, 12 patients (10.4%) had radiofrequency ablation (RFA), 26 patients (22.6%) had transarterial chemoembolization (TACE), 2 (1.7%) had alcohol ablation, and 37 patients (32.2%) had no treatment. Tumor sizes of 9 patients (39.1%) in the transplanted group exceeded the Milan criteria. Mean survival was 72±6.9, 78.8 ±12.5, 19.5±2.8, 20.6±4.2, 16.0±5.9 months in those that received transplantation, resection, RFA, TACE, and no treatment, respectively (p<0.001). Survival was significantly poorer in patients >63 years old (p=0.001), with serum albumin level ≤3.4 g/dL (p=0.01), and with diffuse HCC (p<0.001).
CONCLUSIONS: Survival was significantly better in patients who underwent liver transplantation or surgical resection. Tumo... read more

Keywords: Carcinoma, Hepatocellular, Combined Modality Therapy, Survival Analysis

Related Articles (0)

Coming Soon...

Published: 2015-10-01

Organization and Development of Bone Marrow Donation and Transplantation in Poland

Jagoda Filipiak, Małgorzata Dudkiewicz, Jarosław Czerwiński, Karolina Kosmala, Anna Łęczycka, Piotr Malanowski, Jolanta Żalikowska-Hołoweńko, Piotr Małkowski, Roman Danielewicz

Ann Transplant 2015; 20:588-595

DOI: 10.12659/AOT.894285

Published: 2015-09-29

Risk Factors for Chronic Renal Insufficiency Following Cardiac Transplantation

Kim Lachance, Michel White, Simon de Denus

Ann Transplant 2015; 20:576-587

DOI: 10.12659/AOT.893788